Friday, June 16, 2017 12:09:51 PM
Is the Market Wrong About Bristol-Myers Squibb?
There's a lot of negativity about Bristol-Myers Squibb's prospects. Is it too negative?
Keith Speights (TMFFishBiz) Jun 15, 2017 at 3:21PM
Bristol-Myers Squibb (BMS) (NYSE:BMY) might be the pharmaceutical company equivalent of the late comedian Rodney Dangerfield. Dangerfield's money-line during his career was, "I don't get no respect." BMS executives and shareholders could be saying the same thing these days. The stock is down nearly 30% after disappointing clinical study results for cancer drug Opdivo were announced in August 2016.
The drugmaker's chief scientific officer, Thomas Lynch, got a taste of the negativity associated with Bristol-Myers Squibb when he answered questions at the Goldman Sachs Healthcare Conference on Wednesday. Lynch seemed to be on the defensive during most of the session, with plenty of skeptical questions about the prospects for Opdivo. His responses, though, prompted a question in my mind: Is the market possibly wrong about Bristol-Myers Squibb?
Arrow sign post with mistake
IMAGE SOURCE: GETTY IMAGES.
Reading too much into Checkmate-012 results?
Lynch was asked about the negative reaction by investors to Bristol-Myers Squibb's update on its Checkmate-012 study of Opdivo combined with Yervoy at the American Society of Clinical Oncology (ASCO) meeting earlier this month. The updated two-year survival data from this study showed the overall survival rate fell off dramatically for patients with 50% or greater PD-L1 expression after two years, compared to after one year.
He pointed out two important things to note about the Checkmate-012 study results. First, there were 12 patients with those high levels of PD-L1 expression taking Opdivo only, and 13 patients over-expressing PD-L1 taking the Opdivo/Yervoy combination. That's a very low sample size upon which to base any conclusions.
Second, Lynch noted strong progression-free survival (PFS) rates. He also discussed why PFS is more closely related to the activity of the drug(s) being taken. In fact, Merck (NYSE:MRK) won approval for Keytruda as a first-line treatment of lung cancer based on clinical data that showed only PFS improvement, and not OS improvement.
Are some investors reading too much into the Checkmate-012 results? I think so.
Too pessimistic about Checkmate-227?
Bristol-Myers Squibb expects to report initial results from its Checkmate-227 study by early 2018. This study is evaluating Opdivo in combination with chemotherapy in treating non-small cell lung cancer (NSCLC). A comment was made at the conference on Wednesday that investors don't feel as confident about the study after the Checkmate-012 results.
Lynch stressed that findings from the 012 study simply can't be used to predict what might happen in the 227 study. And he's right.
Lynch is also correct to caution against reading too much into how its 227 study could fare based upon results from AstraZeneca's (NYSE:AZN) late-stage MYSTIC study of Imfinzi (durvalumab) as a monotherapy, and in combination with tremelimumab in treating first-line NSCLC. AstraZeneca should announce those results within the next few weeks.
I also think that Lynch answered wisely when asked if investors were underestimating the opportunity for Opdivo as a monotherapy in treating first-line NSCLC. He noted that the 227 study includes an arm evaluating the drug as a stand-alone treatment and added, "We'll see where that takes us."
The bottom line is that Checkmate-227 stands on its own. Too much pessimism (or optimism, for that matter) is premature at this stage.
Forgetting there's more than just Opdivo?
Lynch did have an opportunity to discuss Bristol-Myers Squibb's pipeline beyond Opdivo, which he described as "incredibly rich." He especially noted the potential for the company's experimental anti-LAG3 and IDO-inhibitor cancer drugs.
But Lynch also reiterated something that BMS CEO Giovanni Caforio said not long ago, "We're not just a cancer company." While he didn't talk much about Bristol-Myers Squibb's products outside of oncology, sales for anticoagulant Eliquis are booming and rheumatoid arthritis drug Orencia is also doing well.
My take is that the market is focused nearly exclusively on possible negatives for Opdivo. I suspect that many are basing their view of BMS' prospects on a "reading of tea leaves" that could turn out to be flat wrong. It could very well turn out that Bristol-Myers Squibb isn't in nearly as bad of a position as some seem to think it is.
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
________________________________________________________
https://www.fool.com/investing/2017/06/15/is-the-market-wrong-about-bristol-myers-squibb.aspx
BMY
Recent BMY News
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • PR Newswire (US) • 04/29/2024 10:00:00 AM
- CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 04/26/2024 10:59:00 AM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Bristol Myers Squibb Reports First Quarter Financial Results for 2024 • Business Wire • 04/25/2024 10:59:00 AM
- Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News • IH Market News • 04/23/2024 11:25:34 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 04/08/2024 03:30:00 PM
- Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy • Business Wire • 04/05/2024 01:05:00 PM
- European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) • Business Wire • 04/03/2024 12:08:00 AM
- Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals • Business Wire • 04/02/2024 10:59:00 AM
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… • Business Wire • 03/28/2024 08:05:00 PM
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease • Business Wire • 03/28/2024 08:01:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde • Business Wire • 03/26/2024 06:25:00 PM
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes • Business Wire • 03/26/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio • Business Wire • 03/25/2024 12:00:00 PM
- Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma • Business Wire • 03/20/2024 08:45:00 PM
- Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma • Business Wire • 03/20/2024 10:59:00 AM
- Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign • Business Wire • 03/19/2024 10:59:00 AM
- Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio • Business Wire • 03/18/2024 12:44:00 PM
- FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy • Business Wire • 03/15/2024 10:27:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM